Cadonilimab plus chemotherapy improves objective response rate to 0.62 in solid tumor patientsMeta-analysis shows cadonilimab plus chemo improves outcomes for solid tumors

Frontiers in Medicine Published May 30, 2026 Study authors: Xiaodong Mi, Tong Lin, Xiaogang Zhu, Li Tian, Juntao Liu, Hong Qin, Shimin Hou, Fei Tuo DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider cadonilimab plus chemotherapy for solid tumors with an objective response rate of 0.62.

This systematic review and meta-analysis evaluated the efficacy and safety of cadonilimab in patients with solid tumors, including gastric cancer, adenocarcinoma of the gastroesoegeal junction, and cervical non-small cell lung cancer. The analysis pooled data from 1,359 patients to assess outcomes for cadonilimab plus chemotherapy versus monotherapy or combination therapy with targeted agents.

Key findings indicate that the combination therapy achieved an objective response rate of 0.62 and a disease control rate of 0.94. Median progression-free survival was 7.47 months and median overall survival was 12.89 months. Subgroup analyses showed an objective response rate of 0.71 for the 10 mg/kg every three weeks dosing schedule.

Safety results reported an incidence rate of adverse events of any grade at 0.99. The incidence of grade 3 or higher treatment-related adverse events was 0.49, while the incidence of grade 3 or higher immune-related adverse events was 0.11. Most prevalent treatment-related adverse events included decreased neutrophil count, anemia, and decreased platelet count. The authors note that follow-up duration was not reported and funding or conflicts were not reported.

This systematic review and meta-analysis examined data from 1,359 patients with solid tumors. The group included people with gastric cancer, adenocarcinoma of the gastroesophageal junction, and cervical non-small cell lung cancer. Researchers compared cadonilimab plus chemotherapy against monotherapy or combination therapy with targeted agents.

The analysis found positive results for objective response rate, disease control rate, progression-free survival, and overall survival. For patients with gastric or gastroesophageal junction adenocarcinoma, the disease control rate was 0.91. In cervical cancer, the objective response rate was 0.63. When using cadonilimab at 10 mg/kg every three weeks, response rates were high and disease control was excellent.

Safety data showed that adverse events occurred in nearly all patients. Serious treatment-related adverse events happened in about half the patients. Grade 3 immune-related adverse events occurred in roughly 11 percent of patients. The most common side effects included decreased neutrophil count, anemia, and decreased platelet count. The study did not report discontinuation rates or specific funding sources.

What this means for you:

This meta-analysis suggests cadonilimab plus chemotherapy may improve outcomes for specific solid tumors with manageable side effects.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

To evaluate the efficacy and safety of cadonilimab in patients with solid tumors. We systematically searched seven databases—PubMed, Embase, Web of Science, Cochrane Library, Ovid MEDLINE, Scopus, and ProQuest—for clinical studies published up to July 19, 2025. Inclusion criteria encompassed randomized controlled trials (RCTs) and single-arm trials. Data collected included objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and adverse events (AEs) incidence. A meta-analysis of relevant data was performed using a random-effects model. This study encompassed a total of 13 investigations, comprising 11 single-arm clinical trials, and 2 randomized controlled trials. A total of 1,359 patients with solid tumors, including gastric cancer or adenocarcinoma of the gastroesophageal junction and cervical non-small cell lung cancer, were enrolled in the study. The pooled efficacy analysis demonstrated an ORR of 0.45 (95% CI: 0.31–0.59), a DCR of 0.84 (95% CI: 0.71–0.94), a median PFS of 7.47 months (95% CI: 4.98–9.97), and a median OS of 12.89 months (95% CI: 10.09–15.68). Subgroup analysis indicated the highest ORR in cervical cancer (0.63, 95% CI: 0.33–0.94), while the highest DCR was observed in gastric or gastroesophageal junction adenocarcinoma (0.91, 95% CI: 0.82–1.00). The administration of cadonilimab at a dosage of 10 mg/kg every three weeks resulted in the optimal ORR and DCR of 0.71 (95% CI: 0.63–0.80) and 0.95 (95% CI: 0.90–0.99), respectively. A comparison of cadonilimab plus chemotherapy with monotherapy or combination therapy with targeted agents revealed that the former demonstrated superior efficacy, with an ORR and DCR of 0.62 (95% CI: 0.56–0.69) and 0.94 (95% CI: 0.88–1.00), respectively. With respect to safety, the incidence rate of adverse events of any grade was 0.99 (95% CI: 0.98–1.00), the incidence of ≥Grade 3 treatment-related adverse events (TRAEs) was 0.49 (95% CI: 0.34–0.63), and the incidence of ≥Grade 3 immune-related adverse events (irAEs) was 0.11 (95% CI: 0.08–0.14). The most prevalent TRAEs included neutrophil count decreased, anemia, and platelet count decreased. Cadonilimab demonstrates a positive response in the treatment of various solid tumors, exhibiting good tolerability. https://www.crd.york.ac.uk/prospero/, identifier CRD420251103576.

Cadonilimab plus chemotherapy improves objective response rate to 0.62 in solid tumor patientsMeta-analysis shows cadonilimab plus chemo improves outcomes for solid tumors

Study Details

Guselkumab Phase III trials validate 3VAS and 4VAS measures for psoriatic arthritis disease activity assessment

Study checks how well pain scores track joint damage in psoriatic arthritis patients

Clinical research that matters. Delivered to your inbox.

Cadonilimab plus chemotherapy improves objective response rate to 0.62 in solid tumor patientsMeta-analysis shows cadonilimab plus chemo improves outcomes for solid tumors

More on Cancer

Study Details

Guselkumab Phase III trials validate 3VAS and 4VAS measures for psoriatic arthritis disease activity assessment

Study checks how well pain scores track joint damage in psoriatic arthritis patients

Clinical research that matters. Delivered to your inbox.

Related in Dermatology

From Other Specialties